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Case Presentation
A 73 year-old-male first sought medical care
for his current condition 6 months before our
evaluation, when he presented to his private
physician complaining of a 1-year history of
cough and dyspnea. A chest X ray at that time
revealed bilateral interstitial fibrosis and a left-
sided pleural density. A biopsy of the left
pleural density showed marked pleural fibrosis
associated with a malignant neoplasm most
consistent with poorly differentiated adeno-
carcinoma. Periodic acid–Schiff staining
showed sparse intracytoplasmic mucin in the
neoplastic cells, which suggested an adenocar-
cinoma. The surrounding lung tissue dis-
played focal interstitial fibrosis and numerous
non-caseating granulomas. Based on the
patient’s history of beryllium work, a lym-
phocyte proliferation test was obtained and
was positive for beryllium sensitization.
Abdominal computed tomography (CT),
brain magnetic resonance imaging (MRI),
and whole-body radionuclide scans showed
no evidence of an extrapulmonary primary
tumor. A chest CT showed diffuse interstitial
markings, a loculated pleural effusion, a tiny
speculated density in the left subapical
region, and mild mediastinal adenopathy. 
The patient’s occupational history is
remarkable because he spent the majority of
his working life at a single governmental
research facility specializing in weapons
development. He began working there in
1959 and spent the first 3 years as a mainte-
nance mechanic, repairing and maintaining
air conditioners, chillers, boilers, and other
facility operations. In 1962, he began work-
ing as a chemistry technician where he fre-
quently worked directly with beryllium. This
job involved pouring and measuring berylli-
um oxide, growing beryllium crystals, and
molding beryllium oxide into experimental
nuclear reactor parts using hot presses and
graphite dyes. He was also involved in both
the setup and cleanup of numerous experi-
ments using beryllium, including cleaning
machinery and bagging contaminated parts.
The patient worked with beryllium on
almost a daily basis from 1962 until 1964,
and then for a few weeks per year until 1975.
The patient stated that his work with
beryllium was mostly done in a controlled
environment. For example, the pouring and
measuring of beryllium oxide was always
done under a vacuum hood. The growing of
beryllium crystals and the experiments
involving beryllium were typically performed
in an enclosed box or vacuum bag. The
patient also reported that when handling
contaminated parts or cleaning after an
experiment, he typically wore a respirator,
gloves, and a lab coat. Despite these controls,
the patient did not remember any strict for-
mal decontamination procedures. He did not
always immediately wash or shower after this
work, and he frequently took his work
clothes home. The patient also stated that
although he occasionally wore a respirator, it
may not have fit well because he frequently
smelled fumes while wearing it. 
During this same period, the patient was
also exposed to asbestos. This occurred as he
removed, cut, and replaced asbestos insula-
tion used in furnaces. He did this approxi-
mately 1 or 2 hr/week; visible dust was 
produced during these procedures until strict
controls were enforced in the early 1970s.
From 1975 until 1987, the patient worked
as a research technician in the tritium labora-
tory at the same facility, where he worked on
various testing projects involving experimen-
tal nuclear reactors. He wore a radiation
badge, but denied ever having “burned out”
(reached acute or cumulative badge readings
above the facility’s allowable limits). He also
denied ever being involved in any acute radi-
ation accidents. The patient’s cumulative
radiation exposure was unknown, but cumu-
lative radiation levels have been determined
in other workers at this facility, and have
generally been well below those associated
with cancer (1,2).
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Occupational medicine physicians are frequently asked to establish cancer causation in patients
with both workplace and non-workplace exposures. This is especially difficult in cases involving
beryllium for which the data on human carcinogenicity are limited and controversial. In this
report we present the case of a 73-year-old former technician at a government research facility
who was recently diagnosed with lung cancer. The patient is a former smoker who has worked
with both beryllium and asbestos. He was referred to the University of California, San Francisco,
Occupational and Environmental Medicine Clinic at San Francisco General Hospital for an eval-
uation of whether past workplace exposures may have contributed to his current disease. The goal
of this paper is to provide an example of the use of data-based risk estimates to determine causa-
tion in patients with multiple exposures. To do this, we review the current knowledge of lung
cancer risks in former smokers and asbestos workers, and evaluate the controversies surrounding
the epidemiologic data linking beryllium and cancer. Based on this information, we estimated
that the patient’s risk of lung cancer from asbestos was less than his risk from tobacco smoke,
whereas his risk from beryllium was approximately equal to his risk from smoking. Based on
these estimates, the patient’s workplace was considered a probable contributing factor to his
development of lung cancer. Key words: berylliosis, beryllium, lung neoplasms, occupational dis-
eases, smoking. Environ Health Perspect 108:1003–1006 (2000). [Online 11 September 2000]
http://ehpnet1.niehs.nih.gov/docs/2000/108p1003-1006steinmaus/abstract.html
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The patient’s medical history is noncon-
tributory except that he smoked one pack of
cigarettes per day from 15 to 37 years of age.
He had no close family members who
smoked and no other known occupational or
environmental exposures to lung carcinogens
such as arsenic, chloromethyl ethers, or radon.
Discussion
Estimating exposure. Based on the patient’s
history, the most obvious causes of his can-
cer seemed to be tobacco smoke, beryllium,
and asbestos. We used several methods to
estimate the patient’s exposure and subse-
quent lung cancer risk for each agent. For
tobacco smoke, a relatively precise assess-
ment of exposure could be estimated because
the patient was forthcoming about his past
smoking history, and this history correlated
well with reports in his past medical records.
For beryllium and asbestos, however, per-
sonal exposure data were lacking, so less
direct methods were needed to estimate the
patient’s exposure to these agents. 
According to a verbal report from the
patient’s former employer, general area air
levels of beryllium in the patient’s work site
never exceeded the threshold limit value of 2
µg/m3. Unfortunately, the extent and accura-
cy of these readings is unknown. Air sampling
may miss short-term, high-dose exposures,
especially in areas away from the sampling
device (3–5). Routine air monitoring may
also miss exposures occurring during chang-
ing clothes or other decontamination proce-
dures. Personal sampling, which would have
given a clearer indication of the patient’s
actual exposure, was not performed. 
Despite the lack of direct data, there are
several indications that the patient was high-
ly exposed. The strongest is the fact that the
patient was positive for beryllium sensitiza-
tion and had chronic beryllium disease
(CBD). Although this disease may occur at
low exposures in susceptible individuals (6),
CBD is much more likely to occur in those
with high exposures (6–9). Another indica-
tion that the patient was highly exposed is
that his job duties were similar to those asso-
ciated with high beryllium levels at other
facilities. For example, airborne beryllium
levels nearly 10 times the current threshold
limit value were reported for metal casting in
beryllium processing plants during the
1960s, the same period that our patient was
most likely exposed (10,11). 
Because the patient’s duties involving
asbestos were similar to those of asbestos
insulators (i.e., the removal, cutting, and
replacing of asbestos insulation), data from
other sources could be used to estimate the
patient’s exposure to asbestos. Based on sev-
eral exposure studies, Nicholson (12) esti-
mated that average fibers counts for asbestos
insulators before the 1970s were approxi-
mately 10–15 fiber/cm3 (12). The similar
period and comparable job duties suggest
that this is a reasonable but likely high-range
estimate of our patient’s exposure. 
Does beryllium cause cancer? The
International Agency for Research on Cancer
(IARC) considers beryllium definitely car-
cinogenic to humans (13). This classification
is based primarily on two epidemiologic
studies (14,15) shown in Table 1, which
show small but consistent relative risks.
Several earlier studies reported similar find-
ings, but certain methodological problems
limited their ability to clarify this association
(16–18). In addition to the human epidemi-
ologic data, animal studies showing consis-
tent dose–response increases of lung tumors
in rats and evidence of carcinogenicity in
several other species also support the link
between beryllium and cancer (13,19).
Despite these data, several authors have
raised doubts that a causal association
between beryllium and lung cancer truly
exists (20–25). These doubts are primarily a
result of criticisms aimed at the human epi-
demiologic data. More common criticisms
include the lack of direct exposure data,
unclear dose–response relationships, and
insufficient control of potential confounding
factors such as smoking. 
For example, Steenland and Ward (14)
collected smoking information on only 32%
of the cohort. This 32% may not represent
the entire cohort, and higher than predicted
rates of smoking may actually be responsible
for the effects attributed to beryllium. On the
other hand, the overall smoking rates esti-
mated for the cohort were already high (61%
of the cohort were estimated to be former or
current smokers compared to 65% for the
age–sex-adjusted U.S. population), and there
is no firm evidence to suggest that smoking
rates were substantially higher than this. Even
if they were, the smoking rate in the cohort
would have to be twice as high as that in the
reference population to be responsible for a
relative risk of 2.0. It is hard to imagine that
the rate of smoking within the study cohort
was double that of the reference population
when 65% of the reference population were
current or former smokers. 
Another criticism of the epidemiologic
data linking beryllium to cancer is the sup-
posed lack of clear dose–response relation-
ships. For example, we normally expect to
find a greater risk in workers who were
exposed for longer periods of time, but Ward
et al. (15) reported that the highest risks were
found in workers with the shortest tenure.
This is not necessarily inconsistent with a
true dose response, however. Instead, it may
be related to Ward et al.’s inclusion of both
highly exposed manufacturing workers and
lesser exposed administrative personnel. That
is, an increased risk with shorter tenure may
actually represent an increased exposure in
workers with the most dusty and unpleasant
jobs who were more likely to quit sooner.
Unfortunately, there are no individual expo-
sure data to confirm whether a true dose–
response relationship does or does not exist. 
The lack of individual exposure data has
also been cited as a weakness in these studies.
It should be noted that the exposure misclas-
sification resulting from this lack of data is
likely to be nondifferential. It would there-
fore typically bias the relative risk towards the
null and not produce a spurious association
(26,27). For example, the Ward et al.’s
cohort included all workers in seven berylli-
um processing plants, so it likely included
some unexposed administrative personnel
(15). If this unexposed group were removed
from the study, the relative risk might be
greater. For example, if 30% of the cohort
were unexposed administrative personnel,
removing this group would increase the rela-
tive risk from 1.26 to approximately 1.40. 
Although the evidence linking beryllium
to cancer is somewhat controversial, dismiss-
ing beryllium as a potential carcinogen based
on our current knowledge appears unwar-
ranted, especially in light of the extensive
animal data supporting this association. 
Estimating risks. Because of the lack of
quantifiable data, an accurate estimate of this
patient’s beryllium exposure is difficult to
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Table 1. Selected studies of beryllium and lung cancer.
Study Study design Results
Steenland and Ward, 1991 (14) For 689 people in a beryllium case Lung cancer SMR = 2.00
registry, mortality experience in (95% CI, 1.33–2.89; 28 cases). 
1989 was determined and compared For those with chronic beryllium 
to U.S. rates. disease, lung cancer SMR = 1.57 
(95% CI, 0.75–2.89; 10 cases).
Ward et al., 1992 (15) Cohort study of 9,225 males at Respiratory cancer SMR = 1.26 
seven beryllium production or (95% CI, 1.12–1.42; 280 cases). 
processing plants. With crude adjustment for 
smoking, SMR = 1.13. For latency 
> 30 years since first employment, 
SMR = 1.46 (p < 0.01; 134 cases).
Abbreviations: CI, confidence interval; SMR, standardized mortality ratio. 
make. Even if his exposure could be precisely
determined, the current literature provides
very little dose–response data with which to
make an accurate assessment of his risk.
Given these limitations, the clearest indica-
tion of the patient’s risks is provided by
Steenland and Ward (14). This study shows
that individuals with CBD had relative lung
cancer mortality risks of approximately 1.5.
This estimate is supported by Ward et al.
(15). This study included all workers in a
variety of different jobs with varied expo-
sures to beryllium. Thus, the risks estimated
from this study probably represent an aver-
age of highly exposed and minimally
exposed workers. Our patient performed a
variety of job duties, many of which were
the same as those found in beryllium pro-
cessing plants. Therefore, it could be argued
that his exposures were probably similar to
those of the Ward et al. cohort and that his
subsequent risk of lung cancer was close to
the relative risk of 1.5 which Ward et al.
(15) reported for workers with latencies of
over 30 years. 
The patient’s lung cancer risks from
smoking appear to be quite similar to this
estimate. As shown in Figure 1, lung cancer
risks in ex-smokers tend to gradually decline
as the period of cessation increases (28–34).
Although current smokers can have 20- to
30-fold higher risks of lung cancer than non-
smokers, relative risks may drop below 2-fold
10–40 years after quitting. Our patient had a
22 pack-year smoking history, but quit smok-
ing 36 years ago. Table 2 provides further
details on the data from Figure 1 that best
reflect this smoking history. Risks in these ex-
smokers range from 1.07 to 2.10. Our
patient’s lung cancer risk from smoking is
most likely somewhere between these values,
and appears essentially indistinguishable from
that estimated for his beryllium exposure. 
The patient’s risk from asbestos seems to
be lower than his risk attributable to tobacco
smoke or beryllium. His exposures were
probably on the order of 10–15 fibers/cm3.
The patient worked with asbestos for approx-
imately 10 years, but only for 1–2 hr/week or
about 4% of his working time. Therefore, his
cumulative exposure was probably near 4–6
fiber-years (10–15 fibers/cm3 × 10 years ×
4% time). It was estimated that cumulative
lung cancer risk increases approximately 2%
for each fiber-year of exposure (35). This sug-
gests that the patient’s lung cancer risk from
asbestos was near a relative risk of 1.1, and
was therefore probably less than his risk from
beryllium or smoking. 
Conclusion
On the basis of the patient’s medical and
occupational history, there was strong evi-
dence that he was exposed to relatively high
levels of both beryllium and tobacco smoke.
There also seems to be little solid evidence to
dismiss IARC’s assertion that beryllium is car-
cinogenic (13), although some controversy
exists over the quality of the available epi-
demiologic data. On the basis of our review of
the literature, we estimated that the patient’s
lung cancer risk from beryllium was roughly
the same as that from his smoking. If the
patient had been a current smoker or recent
ex-smoker, the patient’s risk from smoking
would have likely been much greater than his
risk from beryllium. Because he had stopped
smoking over 30 years before the diagnosis,
however, we concluded that the patient’s
workplace experience, specifically his exposure
to beryllium, was an important contributing
factor to his development of lung cancer.
Asbestos may have also contributed to the
patient’s disease, but his estimated risk from
this carcinogen appears to be below that of
beryllium and tobacco smoke. 
Given the limited data available, the risk
estimates described in this paper are obviously
inexact. Nonetheless, occupational physicians
are frequently asked to provide some input
on cancer causation in smokers or ex-smokers
exposed to occupational carcinogens such as
beryllium and asbestos. This case provides an
example of the use of data-based risk esti-
mates to determine probable causation in the
common scenario of limited epidemiologic
and exposure information. 
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